Maximum tolerated dose and anti-tumor activity of intraperitoneal cantrixil (Trx-e-002-1) in patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: Phase I study results

Jermaine I. Coward, Minal A. Barve, Ganessan Kichenadasse, Kathleen N. Moore, Paul R. Harnett, Daniel Berg, James S. Garner, Don S. Dizon

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)

Abstract

Survival outcomes in ovarian cancer are poor. The aims of this Phase I progressive design study (NCT02903771) were to evaluate the maximum tolerated dose (MTD), tolerability, and antitumor activity of Cantrixil—a novel third-generation benzopyran molecule—in patients (n = 25) with advanced, recurrent/persistent epithelial ovarian, primary peritoneal, or fallopian tube cancer. All had completed ≥ 2 prior regimens; 3 (12%) had platinum-refractory disease, and 17 (68%) had platinum-resistant disease. Following intraperitoneal (IP) port placement, patients received weekly IP Cantrixil in 3-week cycles as monotherapy (Cycles 1–2), and then in combination with intravenous (IV) chemotherapy (Cycles 3–8). Part A (dose escalation) enrolled 11 patients in 6 dose-level cohorts. An MTD of 5 mg/kg was established with dose-limiting toxicity of ileus. Most treatment-related adverse events were gastrointestinal. Across Parts A and B (dose expansion), 16 (64%) patients received ≥ 1 3-week Cantrixil cycle, and had ≥ 1 post-baseline efficacy measurement available. The results show promising anti-tumor activity in monotherapy (stable disease rate of 56%) and in combination with IV chemotherapy (objective response rate of 19%, disease control rate of 56%, and median progression-free survival of 13.1 weeks). The molecular target and mechanism of action of Cantrixil are yet to be confirmed. Preliminary analysis of stem cell markers suggests that IP Cantrixil might induce ovarian cancer stem cell death and sensitize cells to standard chemotherapy, warranting further evaluation.

Original languageEnglish
Article number3196
Number of pages17
JournalCancers
Volume13
Issue number13
DOIs
Publication statusPublished - 1 Jul 2021
Externally publishedYes

Keywords

  • Intraperitoneal delivery
  • Ovarian cancer
  • Phase I
  • Platinum refractory
  • Platinum resistant

Fingerprint

Dive into the research topics of 'Maximum tolerated dose and anti-tumor activity of intraperitoneal cantrixil (Trx-e-002-1) in patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: Phase I study results'. Together they form a unique fingerprint.

Cite this